The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...
Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results